• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Epilepsy - Pipeline Review, H2 2011 - Product Image

Epilepsy - Pipeline Review, H2 2011

  • Published: September 2011
  • 103 pages
  • Global Markets Direct

Epilepsy - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Epilepsy - Pipeline Review, H2 2011', provides an overview of the Epilepsy therapeutic pipeline. This report provides information on the therapeutic development for Epilepsy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Epilepsy. 'Epilepsy - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Epilepsy.
- A review of the Epilepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Epilepsy Overview
Therapeutics Development
An Overview of Pipeline Products for Epilepsy
Epilepsy Therapeutics under Development by Companies
Epilepsy Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Epilepsy Therapeutics - Products under Development by Companies
Epilepsy Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Epilepsy Therapeutics Development
Johnson & Johnson
Kyowa Hakko Kirin Co., Ltd.
NsGene A/S
Archimedes Pharma Limited
Novartis AG
Eisai Co., Ltd.
Elan Corporation, plc
H Lundbeck A/S
Meiji Holdings Co., Ltd.
Pfizer Inc.
Taro Pharmaceuticals Industries Ltd.
Vertex Pharmaceuticals Incorporated
Sun Pharmaceutical Industries Limited
Aeolus Pharmaceuticals, Inc.
GW Pharmaceuticals plc
Icagen Inc
Anavex Life Sciences Corp.
Ligand Pharmaceuticals Incorporated
Bionomics Limited
NeuroSearch A/S
Catalyst Pharmaceutical Partners, Inc.
NPS Pharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc.
Proximagen Neuroscience plc.
Newron Pharmaceuticals S.p.A.
Paloma Pharmaceuticals, Inc.
Bio-Link
D-Pharm Ltd.
Upsher-Smith Laboratories, Inc.
Snowdon Inc.
BioMAS Ltd.
CREABILIS Therapeutics S.r.l.
MedGenesis Therapeutix Inc.
Supernus Pharmaceuticals, Inc.
Celentyx Ltd.
Nobelpharma Co., Ltd.
Concert Pharmaceuticals, Inc.
Bial Group
Biovista Inc.
Marinus Pharmaceuticals, Inc.
UCB S.A.
Xechem International, Inc
Desitin Arzneimittel GMBH
SK Bio-Pharmaceuticals
Epilepsy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles
Vimpat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Brivaracetam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
E2007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Onfi - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carbamazepine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lyrica - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Midazolam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stedesa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carisbamate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Keppra - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vanquix - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fosphenytoin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carvedilol-CR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Biperiden - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oxcarbazepine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lorazepam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
USL255 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Banzel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SPN-538 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NPC-06 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Epliga - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Clonazepam + Levetiracetam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KW-6485 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
E2080 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ME2080 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Epilepsy Therapeutics – Drug Profile Updates
Epilepsy Therapeutics - Discontinued Products
Epilepsy - Featured News
Aug 30, 2011: Results Of Phase III Study For Eisai's Perampanel Presented At 2011 International Epilepsy Congress
Jul 29, 2011: FDA Provides Response To Perampanel New Drug Application
Jul 27, 2011: Glaxosmithkline's Drug Retigabine Added To NHS Treatment Options
Jul 25, 2011: PK Study Comparing Upsher-Smith's Extended-Release Topiramate Formulation With Topamax Published Online In Epilepsia
Jul 22, 2011: European Medicines Agency To Recall Vimpat 15-MG/ML Syrup
Jul 18, 2011: Upsher-Smith Initiates Phase III Study Of Intranasal Midazolam For Rescue Treatment Of Seizure Clusters In Epilepsy Patients
Jul 18, 2011: Upsher-Smith Initiates Phase III Study Of Intranasal Midazolam For Rescue Treatment Of Seizure Clusters In Epilepsy Patients
Jun 28, 2011: Eisai's Antiepileptic Agent Banzel Receives Approval In Canada
Jun 24, 2011: European Medicines Agency Accepts For Review Eisai's MAA For AMPA Receptor Antagonist Perampanel
Jun 16, 2011: Catalyst Pharmaceutical Reports Positive Non-Clinical Efficacy Results Of CPP-115 For Treatment Of Infantile Spasms
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Epilepsy, H2 2011
Products under Development for Epilepsy – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Johnson & Johnson, H2 2011
Kyowa Hakko Kirin Co., Ltd., H2 2011
NsGene A/S, H2 2011
Archimedes Pharma Limited, H2 2011
Novartis AG, H2 2011
Eisai Co., Ltd., H2 2011
Elan Corporation, plc, H2 2011
H Lundbeck A/S, H2 2011
Meiji Holdings Co., Ltd., H2 2011
Pfizer Inc., H2 2011
Taro Pharmaceuticals Industries Ltd., H2 2011
Vertex Pharmaceuticals Incorporated, H2 2011
Sun Pharmaceutical Industries Limited, H2 2011
Aeolus Pharmaceuticals, Inc., H2 2011
GW Pharmaceuticals plc, H2 2011
Icagen Inc, H2 2011
Anavex Life Sciences Corp., H2 2011
Ligand Pharmaceuticals Incorporated, H2 2011
Bionomics Limited, H2 2011
NeuroSearch A/S, H2 2011
Catalyst Pharmaceutical Partners, Inc., H2 2011
NPS Pharmaceuticals, Inc., H2 2011
Jazz Pharmaceuticals, Inc., H2 2011
Proximagen Neuroscience plc., H2 2011
Newron Pharmaceuticals S.p.A., H2 2011
Paloma Pharmaceuticals, Inc., H2 2011
Bio-Link, H2 2011
D-Pharm Ltd., H2 2011
Upsher-Smith Laboratories, Inc., H2 2011
Snowdon Inc., H2 2011
BioMAS Ltd., H2 2011
CREABILIS Therapeutics S.r.l., H2 2011
MedGenesis Therapeutix Inc., H2 2011
Supernus Pharmaceuticals, Inc., H2 2011
Celentyx Ltd., H2 2011
Nobelpharma Co., Ltd., H2 2011
Concert Pharmaceuticals, Inc., H2 2011
Bial Group, H2 2011
Biovista Inc., H2 2011
Marinus Pharmaceuticals, Inc., H2 2011
UCB S.A., H2 2011
Xechem International, Inc, H2 2011
Desitin Arzneimittel GMBH, H2 2011
SK Bio-Pharmaceuticals, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Epilepsy Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Epilepsy, H2 2011
Products under Development for Epilepsy – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Discovery and Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos